FDA Cmte. To Scrutinize Pulmonary Safety, REMS For Alexza's Inhaled Antipsychotic

FDA's Psychopharmacologic Drugs Advisory Committee will meet Dec. 12 to discuss efficacy and safety of Adasuve, an inhalable version of loxapine, for rapid treatment of agitation in schizophrenic and bipolar patients.